The purpose of this clinical study is to better understand how renal denervation (RDN) affects kidney function, both shortly after and up to a year after the procedure. Renal denervation is a minimally invasive treatment used for patients with high blood pressure that does not respond well to medication ("resistant hypertension"). It works by reducing the activity of nerves that run along the arteries supplying the kidneys, which helps lower blood pressure.
To understand how RDN affects the kidneys, we will measure kidney function in detail and analyse blood and urine samples collected before and after the procedure. This will help researchers see whether the procedure causes changes in the kidneys, and whether some of these changes are linked to better kidney health over time.
≥18 years
eGFR >30 ml/min/1.73m2 (CKD stages 3b and less severe)
Informed consent for study participation provided by the patient or the legal guardian
Patient information and consent to the processing of personal data
Patients in emergency situations
Turbid urine sample on admission
Visible haematuria in the urine sample on admission
Pregnancy
Single group
blood sampling
Diagnostic testBlood samples will be taken to examine the mGFR as parameter for kidney function
Change of a specific protein score in urine between Baseline visit (Day 1) and 12 months follow-up visit
Change of a specific protein score in urine prior to standard of care index procedure and 12 months from index procedure. Samples will be stored until the last patient had the last visit. All measurements will be then done afterwards.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
